A B S T R A C T Patient B. J. witlh chr-oniic myelocytic leukemia excreted 0.5-1.1 g protein per day in the urine. Gel filtration on Sephadex G-75 showed about one-third of this protein to be in molecular weight range 20,000-40,000 (fraction BJC). BJC, prepared from 9 liters of urine by gel filtration, was chromatographed on carboxymethylcellulose. Two BJC2 was found in the urine by immunoelectrophoresis in 10% of patients with neoplastic disease and was not observed in urine of other patients or in human plasma.
INTRODUCTION
A l)revious study here showed that patients with advanced neoplastic disease frequently excrete in the turine proteins in molecular weight range 10,000-50,000 which do not react with antiserum to normal human serum (1) . 25 such proteins were visualized in urine fronm nine patients with disseminated cancer (1) but wvere not isolated or characterized.
The present study focused on one patient with clhroniic myelocytic leukemia in whom "low molectlar weight l)roteinuria" was present. A homogeneous glycoprotein not previously described was isolated, its chemiiical composition was determined, a specific antiserum was produced, and with this antiserum the frequency of urinary excretion of the novel glycoprotein was studied in the general clinical population.
METHODS
The subject, patient B. J., was a 66-yr-old Negro female with a 6-mo history of anorexia, weight loss, and dyspnea on exertion. Clinical evaluation revealed chronic myelocytic leukemia and hypertensive heart disease with congestive failure. Urine protein was reported "2+." On day 11, treatment was begun with busulfan and blood transfusions. Staphylococcal bronchopneumonia developed on day 12, and despite penicillin treatment the patient died on day 15. Chronic myelocytic leukemia was confirmed at autopsy.
To purify and characterize the urinary proteins, these methods were used: (a) (9) , glucosamine (after hydrolysis with 2 N HCl at 100°C for 6 h under vacuum [10] ), and sialic acid (11) .
Antisera to proteins isolated from the urine of B. J. were prepared by injecting the protein, suspended in Freund's adjuvant, into rabbits according to route, dose, and schedule of Campbell, Garvey, Cremer, and Susdorf (12) . ' Abbreviations used in this paper: CEA, carcinoembryonic antigen; CM, carboxymethylcellulose; WBC, white blood cells.
These antisera were applied in double immunodiffusion to random urine samples from 38 normal volunteers (age 6-70 yr) and 284 patients on medical, surgical, and pediatric services at Emory University and Henrietta Egleston Hospitals (see Table I Mancini, Carbonara, and Heremans (13) . With these immunoplates, concentration of the antigen in plasma and in phenol extracts of white blood cells (WBC) was determined by single radial immunodiffusion (13) .
WBC were collected in 50-300 mg batches from normal individuals by a continuous-flow cell separator. Similar quantity of WBC was obtained from leukemic subjects by allowing 10- min ailCi removing the WBC layer.2 WBC were washed three times with 0.9%o NaCl and then extracted witlh phenol according to Springer, Nagai, and Tegtmeyer (14) : the phenol extract was dialyzed against H20 and lyophilized, yielding 6-9 mg/100 mg WBC (wet weight) in both leukemic and normal cells. This material was dissolved in 0.9% NaCl at a concentration of 1-10 mg/ml, and was tested against appropriate antiserum to urinary protein in double immunodiffusion and in single radial immunodiffusion.
RESULTS
Urinary proteins were isolated from patient B. J. during days 2 through 10 of hospitalization. During this period, the patient excreted 0. responding to mol wt > 69,000 (2); "BJB," Kd =0.03-0.13, approximate mol wt 40,000-60,000; "BJC," Kd = 0.13-0.27, mol wt 20,000-40,000; and "BJD," K, = 1.0, representing UV-absorbing substances with mol Nvt < 1,000. Normal hunman seruim shows only peaks "A" and "D"; normal human turine contains olnly peak {nDs; urine from patienits wvitlh intrinisic renal disease shoNrs the same pattern as normal sertum (1) .
Attention was now focused on peak BJC. For pr-eparative purposes, the urine was lyophilized in batches of 300 ml. The resulting powder was dissolved in 50 ml 1 N acetic acid, chromatographed on a 4 X 200-cm column of Sephadex G-75. and BJC recovered by lyophilization. This material was pturified three times by gel filtration oni the 2 X 200 cm coltumn, after whiclh it emerged as a single symmetric peak with median K,, 0.15 (fraction "BJC'," Fig. lb (Fig. 2a) .
13JC' was now analyzed by ion-exchange chromatography on CM-11 ( Fig. 3) , with elution of five fr-actions (BJC1 > BJC5). Each was recovered by lyophilization and examined by acrylamide-gel electrophoresis and immunodiffusion. BjC1 and B3jC2 were homogeneous by electrophoresis both in acrylamide gel and on paper (Fig. 4) Cumulative Volume of Effluent (ml) FIGURE 3 Elution profile from chromatography of 169 mg fraction BJC' on 2 X 30 cm column of CM-11. Mode of elution was as described in reference 3, with addition that at cumulative volume 1,900 ml, eluting solvent was changed to pH 8.0, 1.0 M ammonium acetate.
versus antiserum to BJC' confirmed homogeneity of BJC1 and BJC2 (Fig. 2a) 8.9 and at pH 4.0 (Fig. 4) (Table I ).
2b). Further studies with this antiserum are described below. Studies on protein BJC2 were limited by the quantity available. Acrylamide-gel electrophoresis at pH 8.9 showed one component with mobility slower than that of BJC1 (Fig. 4) . Immunoelectrophoresis against antiserum to either BJC' or to BJC1 showed a single precipitin arc cathodal to that of BJC1 (Figs. 2a and  b) . In amino acid composition BJC2 was indistinguishable from BJC1, but it contained only 2545% as much hexose, sialic acid, and hexosamine (Table  II) 6 Single radial immunodiffusion with antiserum to BJC1. Each 'point shows average +SE of three measurements. Plasmas were diluted to specified extent with 0.9% NaCl before analysis. Plasma and WBC samples are identified as in Fig. 5. 
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Phenol extracts of WBC from four normal individuals did not react in double or single radial immunodiffusion with antiserum to BJC1. Extracts from four of six patients with chronic myelocytic leukemia reacted in both tests. The precipitin line in double diffusion showed a reaction of identity with both BJC1 and BJC2. Only BJC1 was visible in immunoelectrophoresis. By single radial immunodiffusion, concentrations of BJC1 in the four leukemic WBC preparations which contained immunoreactive material were estimated in the range 0.5-1.8 mg/100 mg WBC (wet weight) ' (Fig. 6 ).
DISCUSSION
Leukemic patients frequently excrete low molecular weight proteins in the urine (1) . Of the two classes (BJB and BJC) of low molecular weight urinary protein in BJ, one (BJC) was fractionated and found to contain five or more proteins different' from the 33 presently recognized proteins (16) Table II. normal human plasma. A stronger line of reaction with most leukemic plasmas indicated that the plasma concentration of BJC1 is generally increased in leukemic patients. This conclusion was confirmed by single radial immunodiffusion (Fig. 6 ). Frequent (64-75%) presence of BJC1 in leukemic urine presumably results from the elevated plasma concentration exceeding the renal threshold. BJC1 is not detectable by double immunodiffusion in normal urine, but a substance with its antigenic and electrophoretic properties occurs in urine of 33-75% of patients with disseminated neoplastic disease, chronic inflammatory disease of the gastrointestinal tract, and tuberculosis. BJC1, or a closely similar substance, also frequently appears in the urine during the first week after two types of major surgery.
Normal human plasma contains at least 20 glycoproteins. The total level of protein-bound carbohydrate, and the concentration of one glycoprotein easily measurable (ai-acid glycoprotein), rise in patients with neoplastic disease, and after surgery and other types of trauma (17, 18) . The present experiments add a previously unrecognized member to the system of normal human plasma glycoproteins: BJC1. Its plasma concentration appears to parallel those of total glycoproteins and al-acid glycoprotein under conditions of trauma, neoplasm, and inflammation. Relatively low molecular weight probably accounts for its frequent appearance in the urine in these clinical situations.
BJC2 appears to contain the same protein moiety as BJC1 (as evidenced by amino acid composition and antigenic behavior) but a smaller complement of carbohydrate. By immunoelectrophoresis, this glycoprotein was visualized only in a small proportion of urines from cancer patients. Whether BJC2 is unique to neoplastic disease can be determined only after a potent and specific antiserum to this substance is developed.
We recently found (19) that plasma of patients with cancer frequently contains a glycoprotein with the same protein moiety as ai-acid glycoprotein but subnormal carbohydrate content. The relation between BJC1 and BJC2 may be analogous to that between normal al-acid glycoprotein and the abnormal form found in the plasma of patients with cancer.
Among recently identified cancer-related proteins, carcinoembryonic antigen (CEA), like BJC1, contains more than 40% carbohydrate (20) . However, the following differences show BJC1 and BJC2 are unrelated to CEA: BJC1 contains less than 0.026% of this antigen by radioimmunoassay; and amino acid composition of CEA differs"o from that of BJC1 and BJC2 with regard to 13 of 17 residues.
Immunodiffusion showed material reactive with antiserum to BJC1 in extracts of leukemic but not of normal WBC. Only BJC1 was visualized in the leukemic extracts by immunoelectrophoresis. However, threshold concentration for detection by immunoelectrophoresis is probably higher for BJC2 than BJC1, because of the lesser reactivity of the former with the available antisera (Fig. 6) .
What factors might explain the presence of anti-BJC1-reactive material in plasma of both normal and leukemic individuals, but in WBC of only the latter? Experiments on effect of hepatectomy on incorporation of radioactive monosaccharide into circulating glycoproteins of normal and tumor-bearing rats have shown (21, 22) that in the normal animal, plasma glycoproteins are made exclusively in the liver, and that in the tumor-bearing rat, a portion of these glycoproteins arises in extrahepatic, presumably neoplastic tissue. Probably BJC1, like other components of the plasma glycoprotein system, is normally synthesized in liver and released into plasma. In leukemia and perhaps other neoplastic conditions, the glycoprotein may also be synthesized by malignant cells. Alternatively, BJC1 or BJC2 might be adsorbed from plasma onto the surface of the leukemic, but not normal, WBC. Whether or not such adsorption occurs might relate to known differences in surface structure of leukemic versus normal cells (23) . ACKNOWLEDGMENT This investigation was supported by U. S. Public Health Service Grants CA12646 and RR-39.
